| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
15.85(B) |
| Last
Volume: |
2,050,602 |
Avg
Vol: |
1,333,523 |
| 52
Week Range: |
$92.79 - $212.65 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 11.4 |
| Insider 6 Months : 11.4 |
| Insider 3/6 Months : 23.2 |
|
| Guru Rank Number : 691 |
| Guru Rank Value : 2.3 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
7,330 |
7,330 |
7,330 |
7,330 |
| Total Buy Value |
$991,672 |
$991,672 |
$991,672 |
$991,672 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
6,815 |
22,740 |
| Total Sell Value |
$0 |
$0 |
$1,357,080 |
$4,648,975 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
5 |
17 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ostadan Omead |
SVP Mktg, Prod & Strat Plan |
• • – |
2019-12-10 |
4 |
AS |
$326.01 |
$391,212 |
D/D |
(1,200) |
7,844 |
|
- |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2019-12-06 |
4 |
AS |
$325.00 |
$325,000 |
D/D |
(1,000) |
38,665 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2019-12-02 |
4 |
AS |
$320.15 |
$200,094 |
D/D |
(625) |
11,803 |
|
- |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2019-12-02 |
4 |
AS |
$320.33 |
$209,816 |
D/D |
(655) |
3,576 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2019-11-29 |
4 |
AS |
$320.00 |
$285,440 |
D/D |
(892) |
3,461 |
|
- |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2019-11-14 |
4 |
AS |
$300.00 |
$46,500 |
D/D |
(155) |
1,506 |
|
- |
|
| Mcginnis Karen K |
VP, Chief Accounting Officer |
• • – |
2019-11-14 |
4 |
D |
$298.44 |
$34,619 |
D/D |
(116) |
2,153 |
|
- |
|
| Desouza Francis A |
President and CEO |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$1,189,339 |
D/D |
(3,953) |
57,647 |
|
- |
|
| Ronaghi Mostafa |
SVP & CTO |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$354,425 |
D/D |
(1,178) |
75,407 |
|
- |
|
| Ostadan Omead |
SVP Mktg, Prod & Strat Plan |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$494,630 |
D/D |
(1,644) |
9,041 |
|
- |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$316,214 |
D/D |
(1,051) |
9,141 |
|
- |
|
| Hampton Malcolm Garret |
SVP Clinical Genomics Group |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$148,028 |
D/D |
(492) |
6,924 |
|
- |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$29,786 |
D/D |
(99) |
2,326 |
|
- |
|
| Mcginnis Karen K |
VP, Chief Accounting Officer |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$24,070 |
D/D |
(80) |
2,269 |
|
- |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$342,089 |
D/D |
(1,137) |
39,665 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$359,239 |
D/D |
(1,194) |
261,539 |
|
- |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$246,713 |
D/D |
(820) |
4,249 |
|
- |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$24,972 |
D/D |
(83) |
1,661 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$347,806 |
D/D |
(1,156) |
12,428 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2019-11-05 |
4 |
D |
$300.87 |
$77,925 |
D/D |
(259) |
4,353 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2019-11-01 |
4 |
AS |
$300.10 |
$187,563 |
D/D |
(625) |
13,584 |
|
- |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2019-11-01 |
4 |
AS |
$297.28 |
$497,647 |
D/D |
(1,674) |
10,192 |
|
- |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2019-11-01 |
4 |
AS |
$297.28 |
$57,375 |
D/D |
(193) |
5,069 |
|
- |
|
| Tousi Susan H |
SVP Product DevelopmentOfficer |
• – – |
2019-10-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,802 |
|
- |
|
| Ronaghi Mostafa |
SVP & CTO |
• • – |
2019-10-15 |
4 |
AS |
$309.89 |
$1,243,711 |
D/D |
(4,000) |
76,585 |
|
- |
|
3466 Records found
|
|
Page 19 of 139 |
|
|
2.54 (2.29%) 
